SLC25A22 (solute carrier family 25) is a glutamate carrier, present in the mitochondria. It has a predominant expression in the developing brain. It belongs to SLC25 family of mitochondrial transporters, and is localized to human chromosome 11p15.5. The encoded protein is composed of 323 amino acids, and apart from brain is expressed in pancreas, heart, lung, liver, testis, kidney, small intestine and spleen. It has a molecular weight 32.8kDa.
Synonyms: Anti-FLJ13044; Anti-GC1; Anti-NET44; Anti-solute carrier family 25 (mitochondrial carrier: glutamate), member 22
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: SLC25A22 (solute carrier family 25) catalyzes the exchange of L-glutamate with OH-, or co-transports L-glutamate with H-. Missense mutation (p.Pro206Leu) in this gene is linked to myoclonic epilepsy, and might also provide insights into pathophysiology of severe neonatal epilepsies with suppression bursts. Mutation G110R occurring in the transmembrane domain of the protein leads to disruption of glutamate transport. This mutation leads to a severe disorder called migrating partial seizures in infancy (MPSI).
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC